A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer

Trial Profile

A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017.
    • 14 Feb 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2017.
    • 20 Apr 2016 Results of group B patients (n=18) presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top